Sinar Mas provided $250m for Dana while Prosperity7 Ventures led a tranche that took Insilico’s series D round to $95m.

M&A Precision medicine producer Gemini Therapeutics has agreed to merge with Disc Medicine, a US-based haematologic disease therapy developer backed by life sciences real estate investment trust Alexandria Real Estate Equities, pharmaceutical firm Novo and conglomerate Access Industries. The combined entity will operate under the name Disc Medicine and take Gemini’s listing on the Nasdaq…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.